Skip to main content
Top
Published in: European Review of Aging and Physical Activity 1/2016

Open Access 01-12-2016 | Review article

The Contribution of Advanced Glycation End product (AGE) accumulation to the decline in motor function

Authors: Hans Drenth, Sytse Zuidema, Steven Bunt, Ivan Bautmans, Cees van der Schans, Hans Hobbelen

Published in: European Review of Aging and Physical Activity | Issue 1/2016

Login to get access

Abstract

Diminishing motor function is commonly observed in the elderly population and is associated with a wide range of adverse health consequences. Advanced Glycation End products (AGE’s) may contribute to age-related decline in the function of cells and tissues in normal ageing. Although the negative effect of AGE’s on the biomechanical properties of musculoskeletal tissues and the central nervous system have been previously described, the evidence regarding the effect on motor function is fragmented, and a systematic review on this topic is lacking. Therefore, a systematic review was conducted from a total of eight studies describing AGE’s related to physical functioning, physical performance, and musculoskeletal outcome which reveals a positive association between high AGE’s levels and declined walking abilities, inferior ADL, decreased muscle properties (strength, power and mass) and increased physical frailty. Elevated AGE’s levels might be an indication to initiate (early) treatment such as dietary advice, muscle strengthening exercises, and functional training to maintain physical functions. Further longitudinal observational and controlled trial studies are necessary to investigate a causal relationship, and to what extent, high AGE’s levels are a contributing risk factor and potential biomarker for a decline in motor function as a component of the ageing process.
Literature
1.
go back to reference Arvanitakis Z, Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and progression of rigidity and gait disturbance in older persons. Neurology. 2004;63:996–1001.CrossRefPubMed Arvanitakis Z, Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and progression of rigidity and gait disturbance in older persons. Neurology. 2004;63:996–1001.CrossRefPubMed
2.
go back to reference Bellew JW, Symons TB, Vandervoort AA. Geriatric fitness: effects of aging and recommendations for exercise in older adults. Cardiopulm. Phys Ther J. 2005;16:20–31. Bellew JW, Symons TB, Vandervoort AA. Geriatric fitness: effects of aging and recommendations for exercise in older adults. Cardiopulm. Phys Ther J. 2005;16:20–31.
4.
go back to reference Rikkert MGO, Rigaud AS, van Hoeyweghen RJ, de Graaf J. Geriatric syndromes: medical misnomer or progress in geriatrics? Neth J Med. 2003;61:83–7. Rikkert MGO, Rigaud AS, van Hoeyweghen RJ, de Graaf J. Geriatric syndromes: medical misnomer or progress in geriatrics? Neth J Med. 2003;61:83–7.
5.
go back to reference Sehl ME, Yates FE. Kinetics of human aging: I. Rates of senescence between ages 30 and 70 years in healthy people. J Gerontol A Biol Sci Med Sci United States. 2001;56:B198–208.CrossRef Sehl ME, Yates FE. Kinetics of human aging: I. Rates of senescence between ages 30 and 70 years in healthy people. J Gerontol A Biol Sci Med Sci United States. 2001;56:B198–208.CrossRef
6.
go back to reference Bautmans I, Van Puyvelde K, Mets T. Sarcopenia and functional decline: pathophysiology, prevention and therapy. Acta Clin Belg. 2009;64:303–16.CrossRefPubMed Bautmans I, Van Puyvelde K, Mets T. Sarcopenia and functional decline: pathophysiology, prevention and therapy. Acta Clin Belg. 2009;64:303–16.CrossRefPubMed
7.
go back to reference U.S. Department of Health and Human Services. Healthy People 2000 Review. 1999. U.S. Department of Health and Human Services. Healthy People 2000 Review. 1999.
8.
go back to reference Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. Journals Gerontol A, Biol Sci Med Sci. 2001;56:M146–56.CrossRef Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. Journals Gerontol A, Biol Sci Med Sci. 2001;56:M146–56.CrossRef
9.
go back to reference Sternberg SA, Schwartz AW, Karunananthan S, Bergman H, Clarfield AM. The identification of frailty: a systematic literature review. J Am Geriatr Soc. 2011;59:2129–38.CrossRefPubMed Sternberg SA, Schwartz AW, Karunananthan S, Bergman H, Clarfield AM. The identification of frailty: a systematic literature review. J Am Geriatr Soc. 2011;59:2129–38.CrossRefPubMed
10.
go back to reference Sprott RL. Biomarkers of aging and disease: introduction and definitions. Exp Gerontol. 2010;45:2–4.CrossRefPubMed Sprott RL. Biomarkers of aging and disease: introduction and definitions. Exp Gerontol. 2010;45:2–4.CrossRefPubMed
11.
go back to reference Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes, Obes Metab. 2007;9:233–45.CrossRef Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes, Obes Metab. 2007;9:233–45.CrossRef
12.
go back to reference Monnier VM, Mustata GT, Biemel KL, Reihl O, Lederer MO, Zhenyu D, et al. Cross-linking of the extracellular matrix by the maillard reaction in aging and diabetes: an update on “a puzzle nearing resolution.”. Ann N Y Acad Sci. 2005;1043:533–44.CrossRefPubMed Monnier VM, Mustata GT, Biemel KL, Reihl O, Lederer MO, Zhenyu D, et al. Cross-linking of the extracellular matrix by the maillard reaction in aging and diabetes: an update on “a puzzle nearing resolution.”. Ann N Y Acad Sci. 2005;1043:533–44.CrossRefPubMed
13.
go back to reference Rahmadi A, Steiner N, Munch G. Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer’s disease. Clin Chem Lab Med. 2011;49:385–91.CrossRefPubMed Rahmadi A, Steiner N, Munch G. Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer’s disease. Clin Chem Lab Med. 2011;49:385–91.CrossRefPubMed
14.
go back to reference Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. Journals Gerontol A, Biol Sci Med Sci. 2007;62:427–33.CrossRef Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. Journals Gerontol A, Biol Sci Med Sci. 2007;62:427–33.CrossRef
15.
go back to reference Van Puyvelde K, Mets T, Njemini R, Beyer I, Bautmans I. Effect of advanced glycation end product intake on inflammation and aging: a systematic review. Nutr Rev. 2014;72:638–50.CrossRefPubMed Van Puyvelde K, Mets T, Njemini R, Beyer I, Bautmans I. Effect of advanced glycation end product intake on inflammation and aging: a systematic review. Nutr Rev. 2014;72:638–50.CrossRefPubMed
16.
go back to reference Luevano-Contreras C, Chapman-Novakofski K. Dietary advanced glycation end products and aging. Nutrients. C. Luevano-Contreras, Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL 61801, United States; 2010;2:1247–65. Luevano-Contreras C, Chapman-Novakofski K. Dietary advanced glycation end products and aging. Nutrients. C. Luevano-Contreras, Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL 61801, United States; 2010;2:1247–65.
17.
go back to reference Peppa M, Uribarri J, Vlassara H. Aging and glycoxidant stress. Hormones (Athens). 2008;7:123–32. Peppa M, Uribarri J, Vlassara H. Aging and glycoxidant stress. Hormones (Athens). 2008;7:123–32.
18.
go back to reference Gasser A, Forbes JM. Advanced glycation: implications in tissue damage and disease. Protein Pept Lett. 2008;15:385–91.CrossRefPubMed Gasser A, Forbes JM. Advanced glycation: implications in tissue damage and disease. Protein Pept Lett. 2008;15:385–91.CrossRefPubMed
19.
go back to reference Munch G, Westcott B, Menini T, Gugliucci A. Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids. 2012;42:1221–36.CrossRefPubMed Munch G, Westcott B, Menini T, Gugliucci A. Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids. 2012;42:1221–36.CrossRefPubMed
20.
go back to reference Hobbelen JS, Tan FE, Verhey FR, Koopmans RT, de Bie RA. Prevalence, incidence and risk factors of paratonia in patients with dementia: a one-year follow-up study. Int Psychogeriatr. 2011;23:1051–60.CrossRefPubMed Hobbelen JS, Tan FE, Verhey FR, Koopmans RT, de Bie RA. Prevalence, incidence and risk factors of paratonia in patients with dementia: a one-year follow-up study. Int Psychogeriatr. 2011;23:1051–60.CrossRefPubMed
21.
go back to reference Magelhaes PMJ, Appell H, Duarte JA. Involvement of advanced glycation end products in the pathogenesis of diabetic complications: the protective role of regular physical activity. Eur Rev Aging Phys Act. 2008;17. Magelhaes PMJ, Appell H, Duarte JA. Involvement of advanced glycation end products in the pathogenesis of diabetic complications: the protective role of regular physical activity. Eur Rev Aging Phys Act. 2008;17.
22.
go back to reference Kjaer M. Role of extracellular matrix in adaptation of tendon and skeletal muscle to mechanical loading. Physiol Rev. 2004;84:649–98.CrossRefPubMed Kjaer M. Role of extracellular matrix in adaptation of tendon and skeletal muscle to mechanical loading. Physiol Rev. 2004;84:649–98.CrossRefPubMed
23.
go back to reference Avery NC, Bailey AJ. Enzymic and non-enzymic cross-linking mechanisms in relation to turnover of collagen: relevance to aging and exercise. Scand J Med Sci Sports. 2005;15:231–40.CrossRefPubMed Avery NC, Bailey AJ. Enzymic and non-enzymic cross-linking mechanisms in relation to turnover of collagen: relevance to aging and exercise. Scand J Med Sci Sports. 2005;15:231–40.CrossRefPubMed
24.
go back to reference Takahashi M. Pentosidine, an advanced glycation endproduct, and arthritis. Curr Rheumatol Rev. 2006;2:319–24.CrossRef Takahashi M. Pentosidine, an advanced glycation endproduct, and arthritis. Curr Rheumatol Rev. 2006;2:319–24.CrossRef
25.
go back to reference Verzijl N, DeGroot J, Ben ZC, Brau-Benjamin O, Maroudas A, Bank RA, et al. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum. 2002;46:114–23.CrossRefPubMed Verzijl N, DeGroot J, Ben ZC, Brau-Benjamin O, Maroudas A, Bank RA, et al. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum. 2002;46:114–23.CrossRefPubMed
26.
go back to reference Verzijl N, Bank RA, TeKoppele JM, DeGroot J. AGEing and osteoarthritis: a different perspective. Curr Opin Rheumatol. 2003;15:616–22.CrossRefPubMed Verzijl N, Bank RA, TeKoppele JM, DeGroot J. AGEing and osteoarthritis: a different perspective. Curr Opin Rheumatol. 2003;15:616–22.CrossRefPubMed
27.
go back to reference Karim L, Tang SY, Sroga GE, Vashishth D. Differences in non-enzymatic glycation and collagen cross-links between human cortical and cancellous bone. Osteoporos Int. 2013;24:2441–7.CrossRefPubMedPubMedCentral Karim L, Tang SY, Sroga GE, Vashishth D. Differences in non-enzymatic glycation and collagen cross-links between human cortical and cancellous bone. Osteoporos Int. 2013;24:2441–7.CrossRefPubMedPubMedCentral
28.
go back to reference Saito M, Saito M, Marumo KMSKM. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos. Int M. 2010;21:195–214. Saito, Department of Orthopaedic Surgery, Jikei University School of Medicine, Minato-ku, Tokyo 105–8461, Japan. Saito M, Saito M, Marumo KMSKM. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos. Int M. 2010;21:195–214. Saito, Department of Orthopaedic Surgery, Jikei University School of Medicine, Minato-ku, Tokyo 105–8461, Japan.
29.
go back to reference Sroga GE, Vashishth D. Effects of bone matrix proteins on fracture and fragility in osteoporosis. Curr. Osteoporos. Rep. 2012;10:141–50. Sroga GE, Vashishth D. Effects of bone matrix proteins on fracture and fragility in osteoporosis. Curr. Osteoporos. Rep. 2012;10:141–50.
30.
go back to reference Schwartz A V, A.V. S. Diabetes Mellitus: Does it Affect Bone? Calcif. Tissue Int. A.V. Schwartz, Dept. of Epidemiol. and Biostatist., Univ. of California San Francisco, San Francisco, CA, United States, United States; 2003;73:515–9. Schwartz A V, A.V. S. Diabetes Mellitus: Does it Affect Bone? Calcif. Tissue Int. A.V. Schwartz, Dept. of Epidemiol. and Biostatist., Univ. of California San Francisco, San Francisco, CA, United States, United States; 2003;73:515–9.
31.
go back to reference Lindsey JB, Cipollone F, Abdullah SM, McGuire DK. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res. 2009;6:7–14.CrossRefPubMed Lindsey JB, Cipollone F, Abdullah SM, McGuire DK. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res. 2009;6:7–14.CrossRefPubMed
32.
go back to reference Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000;1498:99–111.CrossRefPubMed Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000;1498:99–111.CrossRefPubMed
33.
go back to reference Abate M, Schiavone C, Salini V, Andia I. Management of limited joint mobility in diabetic patients. Diabetes, Metab Syndr Obes Targets Ther. 2013;6:197–207.CrossRef Abate M, Schiavone C, Salini V, Andia I. Management of limited joint mobility in diabetic patients. Diabetes, Metab Syndr Obes Targets Ther. 2013;6:197–207.CrossRef
34.
go back to reference Atienzar P, Abizanda P, Guppy A, Sinclair AJ. Diabetes and frailty: An emerging issue. Part 1: Sarcopaenia and factors affecting lower limb function. Br J Diabetes Vasc Dis. 2012;12:110–6.CrossRef Atienzar P, Abizanda P, Guppy A, Sinclair AJ. Diabetes and frailty: An emerging issue. Part 1: Sarcopaenia and factors affecting lower limb function. Br J Diabetes Vasc Dis. 2012;12:110–6.CrossRef
35.
go back to reference Lebiedz-Odrobina D, Kay J. Rheumatic manifestations of diabetes mellitus. Rheum Dis Clin North Am. 2010;36:681–99.CrossRefPubMed Lebiedz-Odrobina D, Kay J. Rheumatic manifestations of diabetes mellitus. Rheum Dis Clin North Am. 2010;36:681–99.CrossRefPubMed
36.
go back to reference Milaneschi Y, Tanaka T, Milaneschi Y, Tanaka T, Ferrucci LYMTTLF. Nutritional determinants of mobility. Curr Opin Clin Nutr Metab Care. 2010;13:625–9. L. Ferrucci, Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, MD 21225, United States.CrossRefPubMedPubMedCentral Milaneschi Y, Tanaka T, Milaneschi Y, Tanaka T, Ferrucci LYMTTLF. Nutritional determinants of mobility. Curr Opin Clin Nutr Metab Care. 2010;13:625–9. L. Ferrucci, Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, MD 21225, United States.CrossRefPubMedPubMedCentral
37.
go back to reference Semba RD, Nicklett EJ, Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol A, Biol Sci Med Sci. 2010;65:963–75.CrossRef Semba RD, Nicklett EJ, Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol A, Biol Sci Med Sci. 2010;65:963–75.CrossRef
38.
go back to reference Toth C, Martinez J, Zochodne DW. RAGE, diabetes, and the nervous system. Curr Mol Med. 2007;7:766–76. C. Toth, University of Calgary, Department of Clinical Neurosciences, Calgary, AB T2N 4N1, Canada.CrossRefPubMed Toth C, Martinez J, Zochodne DW. RAGE, diabetes, and the nervous system. Curr Mol Med. 2007;7:766–76. C. Toth, University of Calgary, Department of Clinical Neurosciences, Calgary, AB T2N 4N1, Canada.CrossRefPubMed
41.
go back to reference Rosnow RL, Rosenthal R. Computing contrasts, effect sizes, and counternulls on other people’s published data: General procedures for research consumers. Pyschological Methods, 1996;1:331–40. Rosnow RL, Rosenthal R. Computing contrasts, effect sizes, and counternulls on other people’s published data: General procedures for research consumers. Pyschological Methods, 1996;1:331–40.
42.
go back to reference Cohen J. Statistical Power Analysis for the Behavioural Sciences. 2nd ed. Hillsdale: Erlbaum; 1988. Cohen J. Statistical Power Analysis for the Behavioural Sciences. 2nd ed. Hillsdale: Erlbaum; 1988.
43.
go back to reference Dalal M, Ferrucci L, Sun K, Beck J, Fried LP, Semba RD, et al. Elevated serum advanced glycation end products and poor grip strength in older community-dwelling women. Journals Gerontol - Ser A Biol Sci Med Sci. 2009;64:132–7. R. D. Semba, Baltimore, MD 21205, United States.CrossRef Dalal M, Ferrucci L, Sun K, Beck J, Fried LP, Semba RD, et al. Elevated serum advanced glycation end products and poor grip strength in older community-dwelling women. Journals Gerontol - Ser A Biol Sci Med Sci. 2009;64:132–7. R. D. Semba, Baltimore, MD 21205, United States.CrossRef
44.
go back to reference Momma H, Niu K, Kobayashi Y, Guan L, Sato M, Guo H, et al. Skin advanced glycation end product accumulation and muscle strength among adult men. Eur J Appl Physiol. 2011;111:1545–52.CrossRefPubMedPubMedCentral Momma H, Niu K, Kobayashi Y, Guan L, Sato M, Guo H, et al. Skin advanced glycation end product accumulation and muscle strength among adult men. Eur J Appl Physiol. 2011;111:1545–52.CrossRefPubMedPubMedCentral
45.
go back to reference Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L. Relationship of an advanced glycation end product, plasma carboxymethyl-lysine, with slow walking speed in older adults: the InCHIANTI study. Eur J Appl Physiol. 2010;108:191–5.CrossRefPubMedPubMedCentral Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L. Relationship of an advanced glycation end product, plasma carboxymethyl-lysine, with slow walking speed in older adults: the InCHIANTI study. Eur J Appl Physiol. 2010;108:191–5.CrossRefPubMedPubMedCentral
46.
go back to reference Sun K, Semba RD, Fried LP, Schaumberg DA, Ferrucci L, Varadhan R. Elevated serum carboxymethyl-lysine, an advanced glycation end product, predicts severe walking disability in older women: the women’s health and aging study I. J Aging Res. 2012;2012:586385.CrossRefPubMedPubMedCentral Sun K, Semba RD, Fried LP, Schaumberg DA, Ferrucci L, Varadhan R. Elevated serum carboxymethyl-lysine, an advanced glycation end product, predicts severe walking disability in older women: the women’s health and aging study I. J Aging Res. 2012;2012:586385.CrossRefPubMedPubMedCentral
47.
go back to reference Whitson HE, Arnold AM, Yee LM, Mukamal KJ, Kizer JR, Djousse L, et al. Serum carboxymethyl-lysine, disability, and frailty in older persons: the Cardiovascular Health Study. Journals Gerontol A, Biol Sci Med Sci. 2014;69:710–6.CrossRef Whitson HE, Arnold AM, Yee LM, Mukamal KJ, Kizer JR, Djousse L, et al. Serum carboxymethyl-lysine, disability, and frailty in older persons: the Cardiovascular Health Study. Journals Gerontol A, Biol Sci Med Sci. 2014;69:710–6.CrossRef
48.
go back to reference Tanaka K, Kanazawa I, Sugimoto T. Elevated Serum Pentosidine and Decreased Serum IGF-I Levels are Associated with Loss of Muscle Mass in Postmenopausal Women with Type 2 Diabetes Mellitus. Exp. Clin. Endocrinol. Diabetes. I. Kanazawa. Japan: Department of Internal Medicine 1, Shimane University Faculty of Medicine, Izumo; 2015. p. 693–8501. Tanaka K, Kanazawa I, Sugimoto T. Elevated Serum Pentosidine and Decreased Serum IGF-I Levels are Associated with Loss of Muscle Mass in Postmenopausal Women with Type 2 Diabetes Mellitus. Exp. Clin. Endocrinol. Diabetes. I. Kanazawa. Japan: Department of Internal Medicine 1, Shimane University Faculty of Medicine, Izumo; 2015. p. 693–8501.
49.
go back to reference La Maza MPD, Uribarri J, Olivares D, Hirsch S, Leiva L, Barrera G, et al. Weight increase is associated with skeletal muscle immunostaining for advanced glycation end products, receptor for advanced glycation end products, and oxidation injury. Rejuvenation Res. 2008;11:1041–8.CrossRefPubMed La Maza MPD, Uribarri J, Olivares D, Hirsch S, Leiva L, Barrera G, et al. Weight increase is associated with skeletal muscle immunostaining for advanced glycation end products, receptor for advanced glycation end products, and oxidation injury. Rejuvenation Res. 2008;11:1041–8.CrossRefPubMed
50.
go back to reference Shah KM, Clark BR, McGill JB, Lang CE, Maynard J, Mueller MJ. Relationship between skin intrinsic fluorescence--an indicator of advanced glycation end products--and upper extremity impairments in individuals with diabetes mellitus. Phys Ther. 2015;95:1111–9 9. Department of Physical Therapy, Arcadia University, Clenside, Pennsylvania: American Physical Therapy Association.CrossRefPubMedPubMedCentral Shah KM, Clark BR, McGill JB, Lang CE, Maynard J, Mueller MJ. Relationship between skin intrinsic fluorescence--an indicator of advanced glycation end products--and upper extremity impairments in individuals with diabetes mellitus. Phys Ther. 2015;95:1111–9 9. Department of Physical Therapy, Arcadia University, Clenside, Pennsylvania: American Physical Therapy Association.CrossRefPubMedPubMedCentral
51.
go back to reference Haus JM, Carrithers JA, Trappe SW, Haus JM, Carrithers JA, Trappe SW, et al. Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle. J Appl Physiol. 2007;103:2068–76. T.A. Trappe, Human Performance Laboratory, Ball State Univ., Muncie, IN 47306, United States.CrossRefPubMed Haus JM, Carrithers JA, Trappe SW, Haus JM, Carrithers JA, Trappe SW, et al. Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle. J Appl Physiol. 2007;103:2068–76. T.A. Trappe, Human Performance Laboratory, Ball State Univ., Muncie, IN 47306, United States.CrossRefPubMed
52.
go back to reference Prehogan A, Cohen CI. Motor dysfunction in dementias. Geriatrics. 2004;59(53–4):56,59–60. Prehogan A, Cohen CI. Motor dysfunction in dementias. Geriatrics. 2004;59(53–4):56,59–60.
53.
go back to reference Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47:1324–30.CrossRefPubMed Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47:1324–30.CrossRefPubMed
54.
go back to reference Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Birkeland KI, et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol. 2005;25:815–20.CrossRefPubMed Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Birkeland KI, et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol. 2005;25:815–20.CrossRefPubMed
55.
go back to reference Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF, et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia. 2007;50:1409–17.CrossRefPubMed Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF, et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia. 2007;50:1409–17.CrossRefPubMed
56.
go back to reference Prasad C, Imrhan V, Marotta F, Juma S, Vijayagopal P. Lifestyle and Advanced Glycation End Products (AGEs) burden: its relevance to healthy aging. Aging Dis. 2014;5:212–7.CrossRefPubMedPubMedCentral Prasad C, Imrhan V, Marotta F, Juma S, Vijayagopal P. Lifestyle and Advanced Glycation End Products (AGEs) burden: its relevance to healthy aging. Aging Dis. 2014;5:212–7.CrossRefPubMedPubMedCentral
57.
go back to reference Couppé C, Svensson R, Grosset J, Kovanen V, Nielsen R, Olsen M, et al. Life-long endurance running is associated with reduced glycation and mechanical stress in connective tissue. Age (Omaha). C. Couppé, Department of Physical Therapy, Musculoskeletal Rehabilitation Research Unit, Bispebjerg Hospital, Copenhagen, Denmark, Netherlands; 2014;36:9665. Couppé C, Svensson R, Grosset J, Kovanen V, Nielsen R, Olsen M, et al. Life-long endurance running is associated with reduced glycation and mechanical stress in connective tissue. Age (Omaha). C. Couppé, Department of Physical Therapy, Musculoskeletal Rehabilitation Research Unit, Bispebjerg Hospital, Copenhagen, Denmark, Netherlands; 2014;36:9665.
Metadata
Title
The Contribution of Advanced Glycation End product (AGE) accumulation to the decline in motor function
Authors
Hans Drenth
Sytse Zuidema
Steven Bunt
Ivan Bautmans
Cees van der Schans
Hans Hobbelen
Publication date
01-12-2016
Publisher
BioMed Central
Published in
European Review of Aging and Physical Activity / Issue 1/2016
Print ISSN: 1813-7253
Electronic ISSN: 1861-6909
DOI
https://doi.org/10.1186/s11556-016-0163-1

Other articles of this Issue 1/2016

European Review of Aging and Physical Activity 1/2016 Go to the issue